Lifeboat Foundation

Can we turn up—or dial down—their fervor by tweaking their genes?

Enter a new kind of CRISPR. Known mostly as a multi-tool to cut, snip, edit, or otherwise kneecap an existing gene, this version—dubbed CRISPRa—forcibly turns genes on. Optimized by scientists at Gladstone Institutes and UC San Francisco, the tool is counterbalanced by CRISPRi—“i” for “interference,” which, you guessed it, interferes with the gene’s expression.

Though previously used in immortal cells grown in labs, this is the first time these CRISPR tools are rejiggered for cells extracted from our bodies. Together, the tools simultaneously screened nearly 20,000 genes in T cells isolated from humans, building a massive genetic translator—from genes to function—that maps how individual genes influence T cells.

What if you were told there was a completely natural way to stop your body from aging? The trick: You’d have to hibernate from September to May each year.

With age comes experience. And with experience come sore backs, tired bones, and increased risks from a large number of diseases.

Scientists have long been trying figure out how to stop these aches and pains in our twilight years, and to make us live longer and healthier lives at the same time.

While it’s likely a long way off from being ready for humans, a new study investigating the long-term ‘partial reprogramming’ of cells in mice appears to have produced some very intriguing results.

One of the especially promising therapies to appear in the realm of anti-aging research involves a set of molecules known as Yamanaka factors, which scientists have deployed to rejuvenate aging cells, trigger muscle regeneration and tackle glaucoma. New research at the Salk Institute has sought to build on these short-term and specific use cases by demonstrating how these molecules can reverse signs of aging in middle-aged and elderly mice, with no evidence of health problems following the extended treatment.

The Yamanaka factors at the center of this study are a set of four reprogramming molecules that can reset the molecular clock found in the cells of the body. They do so by returning unique patterns of chemicals known as epigenetic markers, which evolve through aging, to their original states.

Continue reading “Anti-aging molecules safely reset mouse cells to youthful states” »

One group of mice received regular doses of the Yamanaka factors from the time they were 15 months old until 22 months, approximately equivalent to age 50 through 70 in humans. Another group was treated from 12 through 22 months, approximately age 35 to 70 in humans. And a third group was treated for just one month at age 25 months, similar to age 80 in humans.

LA JOLLA—(March 7, 2022) Age may be just a number, but it’s a number that often carries unwanted side effects, from brittle bones and weaker muscles to increased risks of cardiovascular disease and cancer. Now, scientists at the Salk Institute, in collaboration with Genentech, a member of the Roche group, have shown that they can safely and effectively reverse the aging process in middle-aged and elderly mice by partially resetting their cells to more youthful states.

“We are elated that we can use this approach across the life span to slow down aging in normal animals. The technique is both safe and effective in mice,” says Juan Carlos Izpisua Belmonte, co-corresponding author and a professor in Salk’s Gene Expression Laboratory. “In addition to tackling age-related diseases, this approach may provide the biomedical community with a new tool to restore tissue and organismal health by improving cell function and resilience in different disease situations, such as neurodegenerative diseases.”

(Part II) Centenarian Blood Test Analysis (n=1,754)

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Continue reading “Centenarian Blood Test Analysis (n=1,754; Part II)” »

Summary: 3,6’-dithiopomalidomide (DP), an anti-inflammatory drug candidate, protected mouse models of Alzheimer’s disease against cognitive decline by reducing neuroinflammation.

Source: NIH

An anti-inflammatory drug candidate, known as 3,6’-dithiopomalidomide (DP), designed by researchers at the National Institute on Aging (NIA), protected lab mice against cognitive decline by reducing brain inflammation.

Have not heard from Dr West in awhile. Two things stood out in this technical hour: Telomerase in gene therapy has never been properly developed, and their iTR technology has not had animal trials as they wait for funding.

In this #webinar, Dr Michael West, a bioentrepreneur and CEO of AgeX Therapeutics, discussed the work of AgeX Therapeutics, their mission and plan to extend human health and longevity, and exciting new #technologies that could combat #ageing and unlock cellular immortality.

Continue reading “AgeX Therapeutics: Targeting Biological Ageing | Dr Michael D. West” »